STOCK TITAN
  1. Home
  2. News
  3. HRMY

HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PLYMOUTH MEETING, Pa., Dec. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that President and CEO, John C. Jacobs will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PT/ 7:30 p.m. ET.

A live audio webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/. 

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com. 

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com 

Harmony Biosciences Media Contact:
Cate McCanless
202-420-7888
cmccanless@harmonybiosciences.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301708655.html

SOURCE Harmony Biosciences

Stock HRMY logo
Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

HRMY Rankings

#1979 Ranked by Market Cap
#4980 Ranked by Stock Gains
N/A Ranked by Dividends

HRMY Latest News

Apr 30, 2024
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
Apr 30, 2024
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Apr 16, 2024
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
Apr 11, 2024
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
Apr 3, 2024
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

HRMY Stock Data

1.80B
34.79M
19.38%
90.04%
11.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PLYMOUTH MEETING

About HRMY

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.